Interferon responses in viral pneumonias
Abstract
Are interferon-mediated antiviral immune responses beneficial or detrimental in COVID-19?
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For some viral infections, treating patients with proinflammatory cytokines in the early stages of infection can help control the virus before detrimental effects of the immune response occur.
“For some viral infections, treating patients with proinflammatory cytokines in the early stages of infection can help to control the virus before detrimental effects of the immune response occur.73”
From Cytokine storm (2020) · cites this paper as [73]
Cites
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · see citing works
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G. E., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F. G., Dickensheets, H. L., & Donnelly, R. P. (2002) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,867 · see citing works
Interferon-Stimulated Genes: What Do They All Do?
Schoggins, J. W. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015756 · Cited by 1,036 · see citing works
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · see citing works
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Major, J., Crotta, S., Llorian, M., McCabe, T. M., Gad, H. H., Priestnall, S. L., Hartmann, R., & Wack, A. (2020) · Science · doi:10.1126/science.abc2061 · Cited by 488 · see citing works
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Cascio, A. L., Clementi, N., Santis, M. D., Mancini, N., Granucci, F., et al. (2020) · Science · doi:10.1126/science.abc3545 · Cited by 398 · see citing works
IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production
Blazek, K. D., Eames, H. L., Weiss, M., Byrne, A. J., Perocheau, D. P. B., Pease, J. E., Doyle, S. E., McCann, F. E., Williams, R. O., & Udalova, I. A. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140995 · Cited by 217 · see citing works
Hemann, E. A., Green, R. R., Turnbull, J. B., Langlois, R. A., Savan, R., & Gale, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0408-z · Cited by 136 · see citing works
Planet, P. J., Parker, D., Cohen, T. S., Smith, H., Leon, J. D., Ryan, C., Hammer, T. J., Fierer, N., Chen, E. I., & Prince, A. S. (2016) · mBio · doi:10.1128/mbio.01939-15 · Cited by 113 · see citing works
Andreakos, E., Zanoni, I., & Galani, I. E. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.10.007 · Cited by 97 · see citing works
Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectively
Porta, C., Hadj-Slimane, R., Nejmeddine, M., Pampin, M., Tovey, M. G., Espert, L., Alvarez, S., & Chelbi‐Alix, M. K. (2004) · Oncogene · doi:10.1038/sj.onc.1208204 · Cited by 94 · see citing works
Bimonte, S., Crispo, A., Amore, A., Celentano, E., Cuomo, A., & Cascella, M. (2020) · In Vivo · doi:10.21873/invivo.11949 · Cited by 71 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works
- Authors
- Grajales-Reyes, G. E., & Colonna, M.
- Affiliations
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Washington University in St. Louis (US)
- ORCID
- Colonna, Marco
- Venue
- Science
- Published
- 2020-08-07
- Volume
- 369
- Issue
- 6504
- Pages
- 626-627
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3047202996
- Cited by
- 46
- References
- 12
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 13 · 2020: 9 · 2019: 1 · 2018: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- interferon, viral pneumonia, COVID-19 pandemic, SARS-CoV-2, antiviral immunity
- MeSH terms
- Interferon Lambda, Antiviral Agents, Humans, Interferons, Lung, Pneumonia, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
